.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for introduction of patients with MASLD as well as measurement of liver end results in cardio-- renal-- metabolic tests, when information advise mechanistically probable perks as well as clinical protection-- and summarizes considerations for trial layout as well as regulatory commendation.